Cite
HARVARD Citation
Aranow, C. et al. (n.d.). CT-03 Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. Lupus science & medicine. p. A46. [Online].